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An international expert group which includes 30 organisations (pharmaceutical companies, contract
research organisations, academic institutions and regulatory bodies) has shared data on the use of
recovery animals in the assessment of pharmaceutical safety for early development. These data have
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Dogbeen used as an evidence-base to make recommendations on the inclusion of recovery animals in toxi-
cology studies to achieve scientiﬁc objectives, while reducing animal use.
Recovery animals are used in pharmaceutical development to provide information on the potential for
a toxic effect to translate into long-term human risk. They are included on toxicology studies to assess
whether effects observed during dosing persist or reverse once treatment ends.
The group devised a questionnaire to collect information on the use of recovery animals in general reg-
ulatory toxicology studies to support ﬁrst-in-human studies. Questions focused on study design, the
rationale behind inclusion or exclusion and the impact this had on internal and regulatory decisions. Data
on 137 compounds (including 53 biologicals and 78 small molecules) from 259 studies showed wide var-
iation in where, when and why recovery animals were included. An analysis of individual study and pro-
gramme design shows that there are opportunities to reduce the use of recovery animals without
impacting drug development.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
1.1. Background
It is a scientiﬁc, ethical and regulatory requirement that before
any potential new medicine can be administered to humans its
safety must be adequately assessed in animals in order to inform
safe starting doses and clinical safety monitoring for human stud-
ies. To meet this objective, repeat-dose toxicology studies in
rodents and/or non-rodents are typically required by global regula-
tory agencies before a drug can be approved for administration to
humans. These studies aim to characterise the toxicological proﬁle
of the test compound following repeated administration, including
identiﬁcation of potential target organs of toxicity and exposure/
response relationships. This is generally achieved through the use
of three dose groups (i.e. to test low, intermediate and high levels
of the drug), plus a control group. Additional animals are frequently
included in these studies to evaluate the reversibility or recovery of
any toxicities observed during the dosing phase. Once treatment is
complete, these additional animals are retained ‘off-dose’ for a pre-
determined period so that recovery can be assessed. The ‘recovery
phase’ should be of sufﬁcient duration for the drug to clear from
circulation, and/or disengage from its receptor target, and be of ade-
quate time to determine whether the effects observed during the
treatment phase persist, or are partially or fully reversible. Demon-
stration of full or partial reversibility of toxicity can then be used as
part of the overall assessment of the suitability of the drug for
administration to humans. In rare cases, new toxicities may also
be identiﬁed during the recovery phase (i.e. delayed toxicity).
Although it is a regulatory expectation that recovery from toxic
effects will be considered at some point during the drug develop-
ment process, this is not necessarily required prior to ﬁrst-
in-human (FIH) clinical trials and does not necessarily require
the use of dedicated recovery animal groups. Guidance on the
inclusion of recovery animals to support clinical development
phases and the associated regulatory recommendations is given
in the International Conference on Harmonisation (ICH) guidelines,
ICH, M3(R2)Non-clinical Safety Studies for the Conduct of Human
Clinical Trials and Marketing Authorization for Pharmaceuticals and
the recently published accompanying Question and Answer
document (ICH, M3(R2), ICH, M3(R2) Q&A). Guidance on the use
of recovery animals for particular classes of drug include ICH
S6(R1), Preclinical Safety Evaluation of Biotechnology-derived
Pharmaceuticals and ICH S9, Nonclinical Evaluation for Anti-cancer
Pharmaceuticals (ICH, S6(R1), ICH, S9). Relevant extracts from these
guidances are set out in Tables 1 and 2.
Typically, reversibility is assessed through the inclusion of addi-
tional ‘recovery’ animals on toxicology studies at different stages
during the development programme. However, depending on the
speciﬁc study objectives and the nature of the observed changes,the addition of recovery animals may not always be necessary to
determine whether a toxic effect is reversible, and in many cases
an evaluation of reversibility based on scientiﬁc assessment alone
may be sufﬁcient. For example, in cases where the lesions are
known to be reversible, or where toxicities occur at clinically irrel-
evant exposure levels, demonstration of reversibility by inclusion
of recovery animals may not always be necessary or justiﬁable.
Generally, where recovery animals are considered important, they
are only needed to evaluate a particular toxicity or lesion once dur-
ing a development programme and on one clinically relevant dose
group. The ICH M3(R2) Question and Answer document (ICH,
M3(R2) Q&A) (Table 2) gives examples of occasions where inclu-
sion of recovery animal groups may be appropriate, such as where
there is severe toxicity at clinically relevant exposures. However,
the guidance is intentionally ﬂexible and does not provide speciﬁc
information on when it is appropriate to include recovery animals
during the drug development process.
A number of publications have examined the use of recovery
animals in non-clinical toxicology studies, with a focus on the
typical study designs used, including the number of dose groups
that included recovery animals and the number of recovery
animals per group (Baldrick, 2008; Baldrick, 2011; Brennan et al.,
2010; Chapman et al., 2009; Chapman et al., 2012; Chapman
et al., 2010; Clarke et al., 2008; Konigsson, 2010; Lynch et al.,
2009; Pandher et al., 2012; Perry et al., 2013; Smith et al., 2005;
Sparrow et al., 2011). Many of these make recommendations for
appropriate study designs, stating that inclusion of recovery
animals should follow a study/project speciﬁc science-driven
approach to comply with the regulatory expectations whilst
minimising laboratory animal use. However, the majority of the
published literature focuses on studies for biological drugs con-
ducted in non-human primates (NHPs), and/or evaluate inclusion
of recovery groups for individual studies, rather than inclusion in
the development package of new molecules as a whole.
Opinions and practices vary around why, when and how recov-
ery animals should be included on toxicology studies. Given this
uncertainty, recovery animals may be included by default without
speciﬁc consideration of their value or scientiﬁc utility, to reduce
potential perceived regulatory hurdles and/or to prevent repeating
a toxicology study if unexpected toxicity is observed that might
necessitate further evaluation of reversibility to support dosing
in humans. The main reason for inclusion of recovery animals is
to address the reversibility of an effect seen in an earlier study.
However, there are also scientiﬁc reasons for the inclusion of these
additional ‘off-dose’ animals which may not directly assess revers-
ibility, such as to inform clinical dosing, to assess the potential for
delayed toxicity, and/or to gather data on immunogenicity or PK/
PD relationships. Although these reasons may not fall within the
regulatory expectations with regards to the assessment of revers-
ibility, these are examples of how ‘off-dose’ animals may be used
Table 1
International Conference on Harmonisation general guidance regarding the need to assess recovery/reversibility on non-clinical studies to support clinical development.
ICH M3 (R2): Conduct of Nonclinical Safety Studies
D. General principles (1.4) ‘‘The goals of the non-clinical safety evaluation generally include a characterization of toxic effects with respect to target organs, dose
dependence, relationship to exposure, and, when appropriate, potential reversibility.’’
Table 3. Recommended non-clinical studies to support exploratory clinical trials
Footnote c. ‘‘Generally, extended single dose toxicity studies should be designed to evaluate hematology, clinical chemistry, necropsy, and histopathology data
(control and high dose only if no treatment-related pathology is seen at the high dose) after a single administration, with further evaluations conducted 2 weeks
later to assess delayed toxicity and/or recovery.’’
Footnote d. ‘‘A single dose level to assess reversibility/delayed toxicity on day 14 can support the microdose approach. The dose level used need not be the high
dose but should be a dose that is at least 100 times the clinical dose.’’
ICH S6 (R1) Pre-clinical safety evaluation for biotechnology-derived pharmaceuticals
Part I
4. Speciﬁc considerations
4.4. Repeat dose toxicity studies ‘‘A recovery period should generally be included in study designs to determine the reversal or potential worsening of pharma-
cological/toxicological effects, and/or potential delayed toxic effects. For biopharmaceuticals that induce prolonged pharmacological/toxicological effects, recovery
group animals should be monitored until reversibility is demonstrated’’
Part II
3. Study design
Section 3.3 Recovery ‘‘Recovery from pharmacological and toxicological effects with potential adverse clinical impact should be understood when they occur at
clinically relevant exposures. This information can be obtained by an understanding that the particular effect observed is generally reversible/non-reversible or by
including a non-dosing period in at least one study, at least one dose level, to be justiﬁed by the sponsor. The purpose of the non-dosing period is to examine revers-
ibility of these effects, not to assess delayed toxicity. The demonstration of complete recovery is not considered essential. The addition of a recovery period just to
assess potential for immunogenicity is not required.’’
ICH S9 Nonclinical evaluation for anti-cancer pharmaceuticals
II. Studies to support non-clinical evaluation
D. General toxicology (2.4) ‘‘Assessment of the potential to recover from toxicity should be provided to understand whether serious adverse effects are reversible
or irreversible. A study that includes a terminal non-dosing period is called for if there is severe toxicity at approximate clinical exposure and recovery cannot be
predicted by scientiﬁc assessment. This scientiﬁc assessment can include the extent and severity of the pathologic lesion and the regenerative capacity of the organ
system showing the effect. If a study of recovery is called for, it should be available to support clinical development. The demonstration of complete recovery is not
considered essential.’’
5. Notes ‘‘For non-rodent studies, dose groups usually consist of at least 3 animals/sex/group, with an additional 2/sex/group for recovery, if appropriate (see sec-
tion II.D (2.4)). Both sexes should generally be used, or justiﬁcation should be given for speciﬁc omissions.’’
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the reasons for inclusion or exclusion of recovery animals may
differ depending on the molecule class (i.e. the expectation of
off-target toxicity for small molecules or the potential for pro-
longed PD effects for biologicals), the novelty of the target pathway
(i.e. how much prior information is available regarding expected
toxicities, based on pharmacological class or previous experience),
as well as the intended therapeutic area or anticipated target
organs.
This paper evaluates current practices for the use of recovery
animals in order to develop recommendations on considerations
for toxicology study design, with a focus on both small molecule
and biological compounds. Clear opportunities to reduce animal
use and resource have been identiﬁed. In brief, we recommend that
decisions regarding when and if recovery animals are included on
repeat-dose toxicology studies should be based on scientiﬁc con-
siderations, rather than a default approach.
1.2. Working group objectives
The UK National Centre for the Replacement, Reﬁnement and
Reduction of Animals in Research (NC3Rs) industry working group
on recovery animals was launched in 2012 in collaboration with
the Medicines and Healthcare Products Regulatory Agency
(MHRA). The group shared data on the use of recovery animals in
general regulatory toxicology studies in order to make evidence-
based recommendations on where and why recovery animals
should be included to optimise risk assessment for human studies
while reducing animal use, with an initial focus on studies
designed to support FIH clinical trials.
The group was represented by 19 global pharmaceutical com-
panies, 3 contract research organisations (CROs), 2 academic insti-
tutions and 4 regulatory bodies (see author afﬁliations) and was
managed and facilitated by the NC3Rs.2. Methods
A pilot questionnaire was conducted to collect information on
the use of recovery animals in general regulatory toxicology stud-
ies. Based on the breadth of results from this exercise the question-
naire was revised and restricted to pivotal repeat dose studies to
support FIH clinical trials only (Tables 3A and 3B and Table S1).
The questionnaire was therefore designed to examine the use
and value of recovery animal groups in studies to support FIH only,
and was not intended to evaluate the role of recovery animals at
later stages in the development process. Criteria for studies suit-
able for inclusion in the questionnaire were set out by the working
group as follows:
 pivotal studies to support FIH;
 good laboratory practice compliant;
 general toxicology repeat dose studies only and;
 studies carried out since January 2010 (to reﬂect the revision
and addendum of ICH M3 and ICH S6 guidelines).
The questionnaire content was agreed upon by the working
group in advance to ensure accurate interpretation of questions.
Information on molecule type (e.g. small molecule or biological),
therapy area and current clinical status were requested. Questions
focused on study design (e.g. species, recovery duration and the
number of animals used), the rationale behind inclusion or exclu-
sion (case-speciﬁc vs. default inclusion), and the impact that this
had on internal and regulatory decisions. Additional information
considered useful to the analysis was provided in the comments
ﬁeld. A copy of the full questionnaire is provided in Supplementary
Table S1.
To minimise the potential for bias, respondents were asked to
start with their most recent compound and work backwards, sys-
tematically, towards January 2010. Data were collected on studies
Table 2
International Conference on Harmonisation M3 (R2) Non-clinical safety studies for the conduct of human clinical trials and marketing authorisation for pharmaceuticals. Question
and Answer document regarding appropriate assessment of reversibility.
ICH M3 (R2) Non-clinical safety studies for the conduct of human clinical trials and marketing authorisation for pharmaceuticals. Q & A.
Q. When is assessment of reversibility considered to be appropriate and is it important to demonstrate full reversibility or is it sufﬁcient to demonstrate the potential
for full reversibility?
A. Evaluation of the potential for reversibility of toxicity (i.e., return to the original or normal condition) should be provided when there is severe toxicity in a
nonclinical study with potential adverse clinical impact. The evaluation can be based on a study of reversibility or on a scientiﬁc assessment
The scientiﬁc assessment of reversibility can include the extent and severity of the pathologic lesion, the regenerative capacity of the organ system showing the
effect and knowledge of other drugs causing the effect. Thus, recovery arms or studies are not always critical to conclude whether an adverse effect is reversible.
The demonstration of full reversibility is not considered essential. A trend towards reversibility (decrease in incidence or severity), and scientiﬁc assessment that
this would eventually progress to full reversibility, are generally sufﬁcient. If full reversibility is not anticipated, this should be considered in the clinical risk
assessment
A toxicity study that includes a terminal non-dosing period is generally warranted if a scientiﬁc assessment cannot predict whether the toxicity will be reversible
and if:
1. there is severe toxicity at clinically relevant exposures (e.g., 610-fold the clinical exposure) or
2. the toxicity is only detectable at an advanced stage of the pathophysiology in humans and where signiﬁcant reduction in organ function is expected. (The
assessment of reversibility in this case should be considered even at >10-fold exposure multiples.)
A toxicity study that includes a terminal non-dosing period is generally not warranted when the toxicity:
1. can be readily monitored in humans at an early stage before the toxicity becomes severe or
2. is known to be irrelevant to humans (e.g., rodent Harderian gland toxicity) or
3. is only observed at high exposures not considered clinically relevant (see 2 above for exception) or
4. is similar to that induced by related agents, and the toxicity based on prior clinical experience with these related agents is considered a manageable risk
If a study of reversibility is called for, it should be available to support clinical studies of a duration similar to those at which the adverse effects were seen non-
clinically. However, a reversibility study is generally not warranted to support clinical trials of a duration equivalent to that at which the adverse effect was not
observed non-clinically
If a particular lesion is demonstrated to be reversible in a short duration (e.g., 2 week or 1 month) study, and does not progress in severity in longer term studies,
repeating the reversibility assessment in longer term toxicity studies is generally not warranted
If a reversibility study is warranted it is efﬁcient to conduct it as part of a chronic study so that all toxicities of concern can be assessed in a single study provided
that it is not critical to conduct it earlier to support a speciﬁc clinical trial
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dum of ICH M3 and ICH S6 guidelines. However, these revisions
were not adopted by some regulatory authorities until after Janu-
ary 2010 and there were some other minor revisions to guidelines
within the data collection period, including the publication of the
ICH M3 Question and Answer document in March 2012. Data col-
lection was completed in May 2013 (See Tables 3A and 3B).
For each individual study the questionnaire requested the ratio-
nale behind the decision to include or exclude recovery animals.
The group devised a number of tick-box options to cover the most
common rationale experienced by working group members.
Respondents were permitted to tick multiple options and could
use the open text ﬁeld to provide additional information. Options
included general reasons such as ‘company practice’ and ‘perceived
regulatory expectation’ or more case-speciﬁc examples such as ‘lit-
erature/known class effects’, ‘previous internal data on compound’
or ‘signal from prior in vivo study’. For each option ticked we asked
whether this was a case-speciﬁc (related to the compound) or
default reason (related to company practice).
For each study we asked for the impact that inclusion or exclu-
sion of recovery animals had on both internal and regulatory deci-
sion-making. The group created appropriate tick-box options based
on previous experience: impacts such as ‘repeat study with inclu-
sion of recovery’, ‘clinical hold’ and ‘modiﬁcation of longer term
studies’ were included.
For the purpose of the questionnaire, the working group out-
lined a number of deﬁnitions. Recovery animal groups were
deﬁned as additional animals on the dosing groups that were
retained for a pre-determined period of time (the recovery period)
once treatment had been completed. Pivotal studies were deﬁned
as good laboratory practice (GLP) compliant toxicology studies.
Partial recovery was deﬁned as anything between no recovery
and full recovery, and it was left to the respondents as to how this
was interpreted. A default study design was deﬁned as an ‘‘off the
shelf’’ protocol, used historically by the organisation.
All studies included in the questionnaire had undergone
approval through company ethical review and comply with
national regulations (e.g. Animals (Scientiﬁc Procedures) Act 1986(ASPA) and European Directives 86/609/EU or 2010/63/EU for stud-
ies carried out in the UK or EU, respectively). Companies provided
data for between 5 and 12 compounds each. Completed question-
naires were provided in conﬁdence by individual companies and
data were collated and anonymized before analysis by the working
group.
Analyses were separated for small molecules and biologicals,
since a difference in approach to inclusion of recovery animals
was expected due to the different scientiﬁc considerations for
assessing safety between these drug classes.
3. Results
3.1. Overview of the dataset
Data on 137 compounds from 259 studies were collected from
22 pharmaceutical and biotechnology companies, including some
submitted through CROs. For each compound, general information
such as molecule type and therapy area was recorded (Fig. 1A and
B). This was followed by more detailed and speciﬁc information on
the individual studies carried out, such as the number of studies,
species, dosing duration, inclusion of recovery animals and the
number of recovery animals used (Tables 4 and 5 and Tables 8
and 9). Data were collected on the rationale for inclusion or exclu-
sion of recovery animals and the impact this had on internal and
regulatory decision making (Tables 6 and 7 and Tables 10 and 11).
The dataset included small molecules, 163 studies for 78 com-
pounds, and biological compounds, 84 studies for 53 compounds.
There was one synthetic peptide, and ﬁve compounds for which
molecule typewas given as ‘other’ (Fig. 1A). The data spannedawide
range of therapeutic areas, with oncology and neuroscience the
most highly represented areas (Fig. 1B). Therapy area was recorded
as ‘other’ for 17 compounds and was not given for 4 compounds.
Studies were conducted in rat, non-human primate (NHP) or
dog (in 42.1%, 28.2% and 23.9% of studies, respectively), with a
small number of studies carried out in other species, such as mouse
(4.6%), rabbit (0.4%) or mini-pig (0.4%). The duration of the dosing
period ranged from less than one week (single dose study) to a
Table 3A
A basic copy of the questionnaire (not including all tick box and selection options), showing the information requested for each study and compound. Participants were able to
provide information on up to 10 studies per compound, for a maximum of 10 compounds. The complete questionnaire is included in Supplementary Table S1.
Compound information
1 Type of molecule [Select]
2 Therapeutic area [Select]
3 Did the compound go into Phase I clinical trials? [Select]
4 If yes, was Phase I in healthy volunteers or patients? [Select]
5 What is the current status of this compound? [Select]
6 If the compound was dropped, was this due to the non-clinical studies, business decision or other? [Select]
7 Did data from recovery animals help the overall development programme? [Select]
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compound.
The majority of compounds had recovery animals in all studies
conducted to support FIH trials (101/137 compounds; 73.7%). A
smaller proportion of compounds had recovery animals in ‘some’,
but not all studies (11/137 compounds; 8.0%), or did not include
recovery animals in any study (25/137 compounds; 18.2%)
(Fig. 1C). The total number of recovery animals used ranged from
0 to over 100 animals per compound (Fig. 1D).
Data were separated into small molecules and biologicals for
further analysis.3.2. Small molecules
3.2.1. Small molecules – use of recovery animals
Recovery animals were included in all studies carried out for the
majority of small molecules (51/78 compounds; 65.4%), though a
signiﬁcant proportion did not include recovery animals in any
study (18/78 compounds; 23.1%) (Fig. 2A and Table 4).
Fig. 2B shows the number of studies carried out per compound
and the number of studies that included recovery animals.
Typically two studies were carried out per compound (57/78
compounds; 73.1%), one rodent and one non-rodent study, and
recovery groups were usually included in both. Table 4 describes
study designs for small molecules in more detail, looking at the
number of studies carried out, the dosing duration, species, and
inclusion of recovery animals. The most common approach was
one rodent and one non-rodent study (typically rat plus dog or
rat plus NHP), both 4 weeks in duration with recovery animals
included in both studies (27/78 compounds; 35%).
Design of the individual studies with regards to inclusion of
recovery animals were examined in more detail, to determine
which dose groups typically included recovery animals (Fig. 2C
and Table 5), as well as the size of the recovery groups (Table 5).
Recovery animals were included in 111/163 small molecule studies
(68.1%). For each approach, Table 5 also presents the total number
of recovery animals used per study.
For each species, recovery animals were typically included in
the control and one (usually high) dose group only (82/111 stud-
ies; 73.9%). Rat and dog were the most common species used, with
fewer studies conducted in NHPs. Recovery group size varied
depending on the species, with larger group sizes for rodents than
non-rodents.
There were 82 studies in rats, 57 of which included recovery
animals (69.5%). The most common approaches were inclusion of
5M + 5F per group in control plus high dose only, occurring in
19/57 (33.3%) or 10M + 10F per group in control plus high dose
only, occurring in 15/57 studies (26.3%), and resulting in the use
of 20 or 40 recovery animals per study, respectively. However,
the maximum number of recovery animals used in any one study
was 60 rats (10M + 10F in control plus two dose groups).
There were 53 studies in dogs, 35 of which included recovery
animals (66.0%). The most common approach was recovery groupsizes of 2M + 2F in control and high dose group only (25/35 stud-
ies; 71.4%). The total number of recovery animals per study ranged
from 4 to 16 animals.
In total there were 25 studies in NHPs, 15 of which included
recovery animals (60.0%). Recovery group sizes were always
2M + 2F. Recovery animals were either included in control plus
one (10/15 studies; 66.7%) or control plus three dose groups (5/
15 studies; 33.3%), resulting in the use of 8 or 16 recovery animals
per study, respectively.
There were 5 studies in mice, 2 of which included recovery ani-
mals (40.0%). Recovery group sizes for these studies were 0M + 10F
(i.e. females only) in control plus high dose group or 5M + 5F in
control plus four dose groups, resulting in the use of 20 or 50
recovery animals per study, respectively.
Table 5 presents the number of recovery animals per study for
the different approaches used. However, the total numbers of
recovery animals per compound for small molecules ranged from
0 to 88. It should be highlighted here that there were 18 com-
pounds that did not have recovery animals in any study.
3.2.2. Small molecules – rationale
When asked for the rationale behind the decision to include or
exclude recovery animals, respondents were permitted to choose
multiple rationales. Company practice was the most common rea-
son for inclusion of recovery animals: for compounds where recov-
ery animals were included (60/78 compounds), company practice
was given as a rationale for inclusion for 41/60 (68%) compounds.
Table 6 shows the complete list of rationales given for inclusion of
recovery animals. ‘Signal from prior in vivo study’ ranked second
(26/60 compounds; 43%) and ‘perceived regulatory expectation’
was also amongst the top ranked rationales (12/60 compound;
20%). ‘Formal regulatory request’ was rarely given as a reason for
inclusion (only 1/60 compounds; 2%).
There were 18 small molecules that did not include recovery in
any study prior to FIH. The top reason for exclusion of recovery ani-
mals was company practice, suggesting that for some companies it
is their practice not to include recovery animals. Other common
reasons given included ‘lack of signal from prior in vivo study’, ‘pre-
vious internal data’ and ‘no indication of need’. The rationales for
exclusion of recovery animals are given in Table 7.
3.2.3. Small molecules – impact
The impacts given for studies where recovery animals were
included are shown in Table 6. The top impact reported was ‘none’,
accounting for 27/60 small molecules (45%). However, this ques-
tion was left unanswered or the impact was ‘unknown’ in a large
proportion of cases. Speciﬁc impacts such as ‘modiﬁcation of the
clinical programme/longer term studies’ or ‘additional studies’
were less common.
It is important to note that multiple impacts could be chosen
per compound/study. Compounds where a speciﬁc impact was
reported (i.e. not including those described as ‘none’, or ‘unknown’)
accounted for 16/60 (27%) compounds. These included impacts
Table 3B
A basic copy of the questionnaire (not including all tick box and selection options), showing the information requested for each study.
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to decision to terminate’ (1 compound) and ‘reversibility of ﬁndings
led to the removal of a previously set upper dose limit’ (1 compound).
For compounds that did not include recovery animals in any
study (18 compounds) no impacts were reported (Table 7). All 18
of these compounds entered Phase I successfully without recovery
data. At the time the questionnaire was completed in May 2013, 2
of these compounds had been discontinued, 10 remained in Phase
I, and 5 compounds had progressed to Phase II or III. The status of
the remaining compound was unknown.
For compounds where recovery animals were included in
‘some’, but not all studies, there were two cases where the impact
of exclusion was ‘a repeat study with recovery included’ and one
compound where the impact was ‘unknown’, as the compound
had not yet gone into Phase I.
3.3. Biologicals
3.3.1. Biologicals – inclusion of recovery animals
Recovery animals were included in all studies for a large pro-
portion of biologicals (45/53 compounds; 84.9%), though a small
proportion did not include recovery animals in any study (6/53
compounds; 11.3%) (Fig. 3A and Table 8). It should be taken into
consideration that for the majority of biologicals only one study
was carried out, therefore ‘all’ for these compounds indicates inclu-
sion on a single study, usually in the NHP.
Fig. 3B shows the number of studies carried out per compound
and the inclusion of recovery animals. Typically one or two studies
were carried out per compound, with recovery animals almost
always included. Where more than one species was used, recovery
was usually included in both rodent and non-rodent studies.
Table 8 describes approaches for biologicals in more detail, pre-
senting details on the number of studies performed, the dosing
duration, species, and inclusion of recovery animals. The most
common approach was a single study in NHP of 4 or 13 weeks induration including recovery animals, accounting for 19/53
compounds (36%). Typical approaches when two studies were
performed were that there was one rodent and one non-rodent
study (usually rat and NHP); both studies were also usually either
4 or 13 weeks in duration and almost always included recovery
animals: compounds using this approach with recovery animals
included in both studies accounted for 11/53 compounds (21%).
Design of the individual studies with regards to inclusion of
recovery animals were examined in more detail, to determine
which dose groups included recovery animals (Fig. 3C and Table 9)
and the size of the recovery groups used (Table 9). Recovery ani-
mals were included in 69/84 studies (82.1%). For each approach,
Table 9 also presents the total number of recovery animals used
per study.
Recovery animals were always included in the control group,
plus at least one and up to ﬁve dose groups, although inclusion
in ﬁve dose groups was very rare (1 study). The most common
approach was inclusion of recovery groups in control plus three
dose groups (27/69 studies; 39.1%). There was a wide range in
the size of the recovery groups used, dependent in part on the spe-
cies used as outlined below.
In total there were 49 studies in NHPs, 44 of which included
recovery animals. The most common approach used was inclusion
of 2M + 2F recovery animals in the control plus one dose group (11/
44 studies; 25.0%) or 2M + 2F in the control plus three dose groups
(11/44 studies; 25.0%), accounting for 50% of all biological studies
in NHPs and resulting in the use of either 8 or 16 recovery animals
per study, respectively. However, given that the number of dose
groups varied from one to ﬁve dose groups plus control, and recov-
ery group sizes of up to 5M + 5F were used, the total number of
recovery animals per study ranged from 8 to 50 NHPs.
Few dog studies were carried out for biologicals. Of the 6 dog
studies in total only one included recovery animals; 2M + 2F recov-
ery animals were included in the control and two dose groups,
using 12 recovery animals in total.
Table 4
Small molecules: study design and inclusion of recovery animals in pivotal repeat dose toxicology studies to support ﬁrst-in-human clinical trials, including the number of studies
carried out per compound, the main study dosing durations, species used and whether recovery animals were included. The number of small molecule compounds in the dataset
using each approach is indicated in the ﬁnal column. The most common approaches are highlighted in bold.
Small molecules
Number of studies Dosing duration Species Inclusion of recovery animals No. compounds
One study 4w Rat Yes 6
4w NHP Yes 1
13w Mouse No 1
(Total 8 compounds)
Two studies 4w + 4w Rat + dog Both 19
None 8
One (rat) 1
4w + 4w Rat + NHP Both 8
One (rat) 1
2w + 2w Rat + dog Both 4
None 1
One (Rat) 2
2w + 2w Rat + NHP Both 1
None 1
One (NHP) 1
2w + 4w Rat + dog Both 2
4w + 4w Rat + other Both 2
13w + 13w Rat + dog Both 1
Rat + NHP Both 1
1w + 1w Rat + dog Both 1
6w + 6w Rat + NHP Both 1
8w + 8w Rat + dog None 1
4w + 7w Rat + NHP One (7w; NHP) 1
(Total 57 compounds)
Three studies 2w + 13w + 13w Rat + rat + NHP None 3
Rat + rat + dog None 2
4w + 4w + 4w Rat + dog + dog All 2
Rat + rat + dog All 1
Mouse + dog + dog One (dog) 1
2w + 2w + 2w Rat + rat + dog None 1
4w + 4w + 13w Rat + NHP + NHP All 1
(Total 11 compounds)
Four studies 2w + 2w + 2w + 13w Dog + mouse + mouse + mouse Two (2w mouse, 13w mouse) 1
4w + 4w + 4w + 4w Rat + rat + dog + dog All 1
(Total 2 compounds)
NHP = non-human primate; w = week.
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included recovery animals. There was no clear common approach
for study designs using this species. The number of recovery ani-
mals per group ranged from 3M + 3F (1 study) up to 10M + 10F
(4 studies), with 5M + 5F per group being the most common (7
studies). With varying animal numbers per group and inclusion
in control plus one to four dose groups, the number of recovery
animals included ranged from 20 to 100 rats per study.
There were 7 studies in mice, 6 of which included recovery ani-
mals. However, there was no common approach for mouse with
regards to the use of recovery animals. Recovery group sizes ran-
ged from 6M + 6F to 12M + 12F per group and the number of dose
groups recovery animals were included on varied between control
plus one and control plus three dose groups.
Table 9 presents the number of recovery animals per study for
the different approaches used. However, the total numbers of
recovery animals per compound for biologicals ranged from 0 up
to a maximum of 170 animals. There were 6 compounds for which
recovery animals were not included in any study.3.3.2. Biologicals – rationale
When asked for the rationale behind the decision to include or
exclude recovery animals, respondents were permitted to choose
multiple options. For biologicals company practice and/or per-
ceived regulatory requirement were the most common reasons
for inclusion of recovery animals: recovery animals were includedin 47/53 biological compounds, company practice and/or regula-
tory requirement was given as a rationale for inclusion in 34/47
(72.3%) of these. ‘Biotherapeutic’ was also one of the top reasons
for inclusion of recovery animals, given for 24/47 (51%) biologicals.
Table 10 shows the complete list of rationales given for inclusion of
recovery animals for biologicals. More speciﬁc reasons included
‘previous internal data’, ‘literature/known class effects’ or ‘per-
ceived ﬁrst in class’. Rarely, ‘clinical request’ or ‘formal regulatory
request’, were given as reasons for inclusion.
There were 6 biologicals that did not include recovery animals
in any study. The top reasons for exclusion were ‘company prac-
tice’ and ‘lack of signal from prior in vivo study’ suggesting that
for some companies it is their practice not to include recovery ani-
mals, or that recovery animals are only included if there is an indi-
cation of need. The complete list of rationales for exclusion is
shown in Table 11.3.3.3. Biologicals – impact
The impacts reported for studies which included recovery ani-
mals are shown in Table 10. The top impact reported was ‘none’,
accounting for 31/47 biologicals (66%) that included recovery ani-
mals. Impact ‘unknown’ was reported in a small proportion of
cases (5/47 compounds; 10%). This was often accompanied with
the additional text such as ‘we cannot assess the impact as we don’t
know what would have happened if the recovery animals had been
excluded’.
Table 5
Small molecules: inclusion of recovery animals within individual studies, including the recovery group size, the number of dose groups that included recovery animals and the
total number of recovery animals used per study. The number of studies for small molecules included in the dataset which used each approach is indicated in the ﬁnal column.
The most common approaches for each species are highlighted in bold. Please note there was also one study in mini-pig and one study where the species was not speciﬁed. There
was one dog study where the numbers of recovery animals per group and the number of dose groups were not speciﬁed.
Small molecules
Species No. recovery animals per group No. dose groups No. recovery animals used No. studies
NHP 2M + 2F (15 studies) Con + 1 8 10
Con + 3 16 5
(Total 15 studies)
Dog 0M + 2F (1 study) Con + 1 4 1
2M + 2F (31 studies) Con + 1 8 25
Con + 2 12 3
Con + 3 16 3
3M + 3F (1 study) Con + 2 12 1
4M + 4F (1 study) Con + 1 16 1
(Total 35 studies; details not speciﬁed for one dog study)
Rat 3M + 3F (1 study) Con + 1 12 1
4M + 4F (4 studies) Con + 3 32 4
5M + 5F (27 studies) Con + 1 20 19
Con + 2 30 1
Con + 3 40 7
6M + 6F (9 studies) Con + 1 24 8
Con + 3 48 1
10M + 10F (16 studies) Con + 1 40 15
Con + 2 60 1
(Total 57 studies)
Mouse 5M + 5F Con + 4 50 1
0M + 10F Con + 1 20 1
(Total 2 studies)
NHP = non-human primate; M = male; F = female; Con = control.
Table 6
Small molecules: inclusion of recovery animals – rationale and impact. Recovery animals were included in 60/78 small molecules (111/163 studies). Please note that for each
study, respondents were able to choose multiple rationales or impacts.
Small molecules
Ranking Rationale for inclusion No. studies No. compounds No. companies
1 Company practice 76 (68%) 41 (68%) 11
2 Signal from prior in vivo study 39 (35%) 26 (43%) 10
3 Perceived regulatory expectation 24 (22%) 12 (20%) 6
4 Previous internal data on the compound 24 (22%) 15 (25%) 8
5 Oncology drug 24 (22%) 11 (18%) 4
6 Perceived ﬁrst in class 22 (20%) 11 (18%) 5
7 Literature/known class effects 18 (16%) 10 (17%) 6
8 Clinical request (internal or external) 8 (7%) 5 (8%) 4
9 Healthy vs. patient population 4 (4%) 3 (5%) 3
10 Formal regulatory feedback 2 (2%) 1 (2%) 1
11 Unknown 1 (1%) 1 (2%) 1
Ranking Impact of inclusion No. studies No. compounds No. companies
1 None 41 (37%) 27 (45%) 11
2 Unanswered 18 (16%) 15 (25%) 7
3 Unknown 15 (14%) 6 (10%) 4
4 Modiﬁcation of clinical programme 14 (13%) 8 (13%) 6
5 Other 11 (10%) 7 (12%) 4
6 Additional clinical studies 5 (5%) 4 (7%) 3
7 Modiﬁcation of longer term studies 5 (5%) 4 (7%) 4
8 Internal delay 5 (5%) 4 (7%) 3
9 Formal regulatory request 3 (3%) 3 (5%) 3
10 Clinical hold 2 (2%) 2 (3%) 2
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‘additional clinical studies’ and/or ‘modiﬁcation of longer term
studies’ were reported in a smaller proportion of studies. Often,
multiple impacts were given per compound/study. Overall, there
were only 8 compounds for which a speciﬁc impact(s) (i.e. other
than ‘none’ or ‘unknown’) was reported. This included a single
compound with an impact described under ‘other’ in which lack
of reversibility ‘contributed to termination of the compound’.For compounds that did not include recovery animals in any
study (6 compounds) no impacts were reported (Table 11). Of
these 6 compounds, 2 were discontinued prior to Phase I (for rea-
sons unrelated to recovery) and 4 successfully entered Phase I. At
the time the questionnaire was completed (May 2013) one of
these compounds had been subsequently discontinued (for rea-
sons unrelated to recovery) and the other three remained in
Phase I.
Table 7
Small molecules: exclusion of recovery animals – rationale and impact. Recovery animals were not included in any study for 18/78 compounds (41 studies). This table lists the
rationales for not including recovery animals and the impact that this had on internal and regulatory decision-making. Please note that for each study, respondents were able to
choose multiple rationales or impacts.
Small molecules
Ranking Rationale for exclusion No. studies No. compounds No. companies
1 Company practice 28 (68%) 11 (61%) 3
2 Signal (or lack thereof) from prior in vivo study 26 (63%) 10 (56%) 3
3 Previous internal data on the compound 26 (63%) 10 (56%) 2
4 No indication of need 14 (34%) 8 (44%) 5
5 Literature/known class effects (MOA) 4 (10%) 2 (11%) 2
6 Other 1 (2%) 1 (6%) 1
Ranking Impact of exclusion No. studies No. compounds No. companies
1 None – other 41 (100%) 18 (100%) 6
Table 8
Biologicals: study design and inclusion of recovery animals in pivotal repeat dose toxicology studies to support ﬁrst-in-human clinical trials, including the number of studies
carried out per compound, the main study dosing durations, species used and whether recovery animals were included. The number of biological compounds in the dataset using
each approach is indicated in the ﬁnal column. The most common approaches are highlighted in bold.
Biologicals
Number of studies Dosing duration Species Inclusion of recovery animals Number of compounds
One study 4w NHP Yes 10
No 1
13w NHP Yes 9
26w NHP Yes 2
20w NHP Yes 1
2w NHP No 1
8w NHP Yes 1
5w Rabbit Yes 1
13w Mouse Yes 1
(Total 27 compounds)
Two studies 13w + 13w Rat + NHP Both 5
4w + 4w Rat + NHP Both 4
None 1
8w + 8w Rat + NHP Both 2
None 1
4w + 4w Mouse + NHP Both 1
One (NHP) 1
4w + 13w Rat + NHP Both 2
Mouse + NHP
5w + 13w Mouse + NHP Both 1
8w + 8w Rat + dog Both 1
13w + 13w Mouse + NHP Both 1
13w + 26w NHP + mouse Both 1
1w + 4w NHP + Rat Both 1
(Total 22 compounds)
Three studies 4w + 4w + 4w Rat + dog + dog None 1
6w + 6w + 6w Rat + NHP + NHP Two (rat, NHP) 1
4w + 13w + 13w Rat + rat + NHP All 1
(Total 3 compounds)
Four studies 2w + 4w + 4w + 4w Dog + rat + dog + dog None 1
(Total 1 compound)
NHP = non-human primate; w = week.
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animals for compounds where recovery was only included in
‘some’ studies (2 compounds).
4. Discussion
4.1. Current regulatory environment
The purpose of the questionnaire was to analyse current prac-
tices and examine the range of study designs used for assessment
of reversibility of toxicity, as well as the impact this had on internal
or regulatory decisions (from the pharmaceutical company per-
spective). Our data show that a variety of different study designsand approaches are used across the industry. This variation in com-
pany practice offers a possibility for making recommendations to
reduce animal numbers, while taking into consideration interna-
tional regulatory guidances.
Currently, it is a regulatory expectation that recovery from
any toxic effects of a compound will be assessed at some point
during the drug development process. However, there is ﬂexi-
bility in how this may be carried out. Prediction of recovery
based on scientiﬁc assessment, e.g. through literature/known
class effects, prior knowledge of the compound, or information
gained from previous in vivo studies, is encouraged. Speciﬁcally,
the current regulatory guidelines relating to the use of recovery
animals state that inclusion of recovery animals is not always
Table 9
Biologicals: inclusion of recovery animals within individual studies, including the recovery group size, the number of dose groups that included recovery animals and the total
number of recovery animals used per study. The number of studies for biologicals included in the dataset which used each approach is indicated in the ﬁnal column. The most
common approaches for each species are highlighted in bold. Please note there was also one study in rabbit.
Biologicals
Species No. recovery animals per group No. dose groups No. recovery animals used No. studies
NHPs 2M + 2F (29 studies) Con + 1 8 11
Con + 2 12 5
Con + 3 16 11
Con + 4 20 1
Con + 5 24 1
3M + 3F (13 studies) Con + 1 12 4
Con + 2 18 3
Con + 3 24 3
Con + 4 30 3
4M + 4F (1 study) Con + 3 32 1
5M + 5F (1 study) Con + 4 50 1
(Total 44 studies)
Dog 2M + 2F (1 study) Con + 2 12 1
(Total 1 study)
Rat 3M + 3F (1 study) Con + 4 30 1
5M + 5F (7 studies) Con + 1 20 1
Con + 2 30 2
Con + 3 40 4
6M + 6F (4 studies) Con + 1 24 2
Con + 3 48 2
9M + 9F (1 study) Con + 3 72 1
10M + 10F (4 studies) Con + 1 40 1
Con + 3 80 2
Con + 4 100 1
(Total 17 studies)
Mouse 6M + 6F Con + 1 24 1
Con + 3 48 1
7M + 7F Con + 3 56 1
9M + 9F Con + 2 54 1
10M + 10F Con + 1 40 1
12M + 12F Con + 3 96 1
(Total 6 studies)
Please note there was also one study in rabbit which included recovery animals
NHP = non-human primate; M = male; F = female; Con = control.
Table 10
Biologicals: inclusion of recovery animals – rationale and impact. Recovery animals were included in at least one study for 47/53 biological compounds (69/84 studies). This table
lists the rationales for inclusion of recovery animals and the impact that this had on internal and regulatory decision-making. Please note that for each study, respondents were
able to choose multiple rationales or impacts.
Biologicals
Ranking Rationale for inclusion No. studies No. compounds No. companies
1 Company practice 41 (59%) 31 (66%) 11
2 Perceived regulatory expectation 36 (52%) 25 (53%) 6
3 Biotherapeutic 34 (49%) 24 (51%) 10
4 Literature/known class effects 18 (26%) 15 (32%) 6
5 Previous internal data on the compound 13 (19%) 11 (23%) 7
6 Perceived ﬁrst in class 11 (16%) 7 (15%) 5
7 Signal from prior in vivo study 9 (13%) 6 (13%) 5
8 Oncology drug 7 (10%) 5 (11%) 4
9 Clinical request (internal or external) 2 (3%) 2 (4%) 2
11 Other 2 (3%) 1 (2%) 1
10 Formal regulatory feedback 1 (1%) 1 (2%) 1
Ranking Impact of inclusion No. studies No. compounds No. companies
1 None 46 (67%) 34 (72%) 9
2 Other 7 (10%) 5 (11%) 4
3 Unknown 6 (9%) 5 (11%) 5
4 Modiﬁcation of longer term studies 5 (7%) 3 (6%) 3
5 Modiﬁcation of clinical programme 3 (4%) 3 (6%) 3
6 Additional clinical studies 2 (3%) 2 (3%) 2
7 Internal delay 1 (1%) 1 (2%) 1
8 Formal regulatory request 1 (1%) 1 (2%) 1
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Table 11
Biologicals: exclusion of recovery animals – rationale and impact. Recovery animals were not included in any study for 6 biological compounds (13 studies). This table lists the
rationales for not including recovery animals and the impact that this had on internal and regulatory decision-making. Please note that for each study, respondents were able to
choose multiple rationales or impacts.
Biologicals
Ranking Rationale for exclusion No. studies No. compounds No. companies
1 Company practice 11 (85%) 4 (67%) 3
2 Signal (or lack thereof) from prior in vivo study 10 (77%) 4 (67%) 3
3 Previous internal data on the compound 9 (70%) 3 (50%) 2
4 No indication of need 9 (70%) 3 (50%) 2
5 Literature/known class effects (MOA) 8 (62%) 3 (50%) 1
6 Other 1 (8%) 1 (17%) 1
Ranking Impact of exclusion No. studies No. compounds No. companies
1 None 13 (100%) 6 (100%) 4
Fig. 2. Data on the inclusion of recovery animals for small molecule compounds (78 compounds from 163 studies); inclusion of recovery by inclusion of recovery animals in
‘all’, ‘some’ or ‘no’ studies carried out to support FIH per compound (A) and also by the total number of studies carried out per compound (B). For studies on which recovery
animals were included (110 studies) the number of dose groups that they were included on are shown (C).
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toxicity is not essential. Relevant extracts from the regulatory
guidelines on the use of recovery animals are provided in
Tables 1 and 2. These guidelines clearly state that although
assessment of reversibility of toxic effects should be considered,
this does not necessarily need to be demonstrated through
addition of recovery animals, except in particular circum-
stances. This paper aims to provide recommendations and
industry experience to support the information provided in
the regulatory guidelines, to encourage inclusion of recovery
animals only if scientiﬁcally justiﬁed, and to help overcome
perceived regulatory barriers.
4.2. A variety of approaches
In order to capture how recovery animals are currently being
used to support FIH, studies for small molecules and biologicalswere examined to look at (i) approaches used within a drug devel-
opment programme (e.g. rodent vs. non-rodent), (ii) approaches
used within a study (e.g. number of dose groups or number of
animals per group), (iii) the rationale for including or excluding
recovery animals and most importantly (iv) the impact that this
had on internal or regulatory decision-making.
Data on 259 studies from 137 compounds (including 53
biologicals and 78 small molecules) were examined and used as
an evidence-base to make recommendations on the inclusion of
recovery animals in toxicology studies to best assess human safety,
while reducing animal use.
It is important to note that this is a retrospective analysis. Spe-
ciﬁcally, it was not the intention to comment, with the beneﬁt of
hindsight, on how the studies should have been designed. Instead,
the aim was to use the data as an evidence-base to examine cur-
rent practices and formulate recommendations for the use of
recovery animals in future studies.
Fig. 3. Data on the inclusion of recovery animals for biological compounds (53 compounds from 84 studies); inclusion of recovery by inclusion of recovery animals in ‘all’,
‘some’ or ‘no’ studies carried out to support FIH per compound (A) and also by the total number of studies carried out per compound (B). For studies on which recovery
animals were included (69 studies) the number of dose groups that they were included on are shown (C).
F. Sewell et al. / Regulatory Toxicology and Pharmacology 70 (2014) 413–429 425By using historical data, there were some limitations, as the
required information was not always available or the answers
given were ambiguous. This particularly applies to the more sub-
jective questions of rationale and impact of inclusion/exclusion,
which were more difﬁcult to assess. Nevertheless, by looking at
the most common answers given there was a clear indication of
the top rationale and impacts for inclusion/exclusion. Limitations
for the assessment of impact, particularly with regards to inclu-
sion, are described in more detail in the section below.
It is important to note that participation in the survey was vol-
untary and so there was a potential for selection bias. However, an
effort to minimise this bias was made by the selection criteria,
where we requested that respondents provide information for
compounds working backwards systematically, from the most
recent compound back to January 2010.
More objective data were available regarding study design, such
as information on the total number of repeat-dose toxicology stud-
ies carried out per compound, as well as data on the inclusion of
recovery animals (i.e. number of dose groups and number of ani-
mals used per group), from 137 compounds and 22 companies,
across a wide range of therapeutic areas, thus providing a clear pic-
ture of the use of recovery animals across the industry.
4.3. Rationale and impact for inclusion
Analysis of the dataset revealed a wide range in practice regard-
ing the use of recovery animals for both biologicals and small mol-
ecules. Reasons for the different approaches may include risk
aversion (e.g. inclusion of recovery animals in all studies to avoid
the potential need to repeat studies and/or delay to the drug devel-
opment or approval process), prior experience (e.g. the class of drug
is known to cause toxicities that show evidence of reversibility)
and/or use of different default study designs between companies.
Perceived regulatory expectation was one of the top rationales
given for inclusion of recovery animals, despite the ICH guidelinesstating that demonstration of reversibility of toxicity is only
required in certain circumstances. There is a difference in response
between small molecules (22%) and biologicals (52%) suggesting
that regulatory expectation may be more of an issue for biologicals.
The perceived regulatory expectations may reﬂect personal or
company experiences with the regulators, a general sense of risk
aversion to avoid unnecessary delays in drug development and a
desire to progress to clinical trials in patients as rapidly as possible.
For example, there appears to be a reluctance to alter default prac-
tices and omit recovery animals, as it is unknown how regulators
will view the adequacy of the non-clinical safety characterisation
and there remains a potential risk that companies could be asked
to repeat studies to assess recovery (a fairly common reason given
for inclusion of recovery animals was ‘‘we don’t know what would
have happened if recovery animals had not been included’’). Default
company practice was the other most common rationale for inclu-
sion of recovery animals for both small molecules (68%) and bio-
logicals (59%). For instance recovery animals were included in all
repeat-dose studies and in all dose groups for 49% biologicals
and 19% small molecules. However, it should be noted that only
one repeat-dose study was conducted to support FIH trials for a
signiﬁcant number of biologicals (27/53 compounds; 50.1%) exag-
gerating the apparent difference in default company practices rel-
ative to small molecules. Regardless, the common use of a default
approach for either type of compound represents an opportunity to
reduce animal use.
Some compounds did not include recovery animals in any
study: 6/53 (11%) biologicals and 18/78 (23%) small molecules.
Only a small number of compounds (11/137: 8%) included recovery
animals in ‘some’ studies. Within studies, recovery animals were
usually included in the control and either one (typically the high
dose) or all dose groups. For each compound, the same approach
was used for each repeat-dose study that included recovery ani-
mals, suggesting that data from one study were not necessarily
being taken into consideration in the design of subsequent studies.
Table 12
Recommendations. Recovery animals should not be included in general regulatory toxicology unless there is an indication of need. Situations where assessment of recovery may
be warranted are outlined below, as part of a weight-of-evidence assessment. For clarity, situations where inclusion of recovery animals is not warranted have also been included.
If inclusion of recovery animals is scientiﬁcally justiﬁed please refer to Fig. 4 for considerations and recommendations for study design.
Rationale for inclusion of recovery animals in general regulatory toxicology studies. Recovery animals should not be included unless scientiﬁcally justiﬁed. Where
recovery animals are deemed a necessary inclusion, it is recommended that this occurs later in development, once more information is available to inform decisions and
study design.
Weight-of-evidence pointing towards a need to include recovery animals:
 Lack of prior knowledge:
- lack of knowledge of the reversibility of speciﬁc lesion/effect e.g. not a common lesion
- Lack of certainty of the MOA
 Literature/known class effects:
- indication of potentially irreversible (severe) toxicities at clinically relevant exposures (610-fold clinical exposure)
 Previous internal non-clinical data on the compound or a related one:
- signal from prior in vitro or in silico study indicates that more information on reversibility is required
- signal from prior in vivo study (e.g. from a prior study such as dose range ﬁnding) suggests reversibility may be a concern
- suggestion of severe toxicity at clinically relevant exposures (e.g., 10-fold clinical exposure)
 Prior internal clinical experience with class of drug:
- suggests assessment of recovery is necessary (e.g. expected toxicities are not known to recoveror are expected to occur at clinically relevant levels)
ICH, M3(R2) Q&A guidance
 Severe toxicity at clinically relevant exposures (e.g., 610-fold the clinical exposure)
 Toxicity is only detectable at an advanced stage of the pathophysiology in humans and where signiﬁcant reduction in organ function is expected even at clinically
irrelevant exposures (e.g. >10-fold exposure multiples.)
Situations when inclusion of recovery animals is not warranted:
 Reversibility (or lack thereof) can be predicted through scientiﬁc assessment (e.g. prior knowledge of the compound or class of compound) through sources such
as:
- Literature or otherwise known class effects (e.g. prior knowledge of the compound or class of compound and target; lesion effect known to be reversible
or irreversible)
- Previous internal non-clinical data on the compound or a related one
- Prior internal clinical experience with class of drug
- Expert experience on the nature of the lesion and reference to literature and other sources (i.e. toxicity is always reversible or always irreversible)
 Known toxicities only occur at clinically irrelevant doses
ICH, M3(R2) Q&A guidance
 Toxicity is similar to that induced by related agents, and the toxicity based on prior clinical experience with these related agents is considered a manageable risk
 Toxicity is only observed at clinically irrelevant high exposures
 Toxicity of concern is irrelevant to humans (e.g. rodent Harderian gland toxicity)
 Toxicity can be readily monitored in humans at an early stage before the toxicity becomes severe
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internal or regulatory decisions, the most common answer was
‘none’. Although, it is clear in this situation (i.e. no impact) that
data from recovery animals did not inﬂuence internal decision
making, either positively (i.e. to allow the programme to move
forward) or negatively (i.e. it did not hold up compound progres-
sion), we do not know whether the recovery data contributed to
regulatory approval to proceed to human studies. However, these
data do indicate that there was at least no request for additional
recovery data from the regulators. This could be because (i)
recovery had been adequately assessed and/or (ii) there were no
toxicities for which assessment of recovery was deemed necessary.
The second most common answer was that the impact of recovery
data on internal or regulatory decision was ‘unknown’. This was
often accompanied with a statement such as ‘was not discussed
with regulatory agencies what might happen if recovery had not been
included’, which may account for ‘perceived regulatory expectation’
being given as the rationale for inclusion in a signiﬁcant proportion
of cases. In studies where recovery animals were included there
were only four cases where the impact given was a formal regula-
tory request for recovery data (3 small molecules and 1 biological).
In some cases inclusion of recovery animals did impact on the
development programme. Reasons included modiﬁcation of the
clinical programme, requests for longer-term studies and/or clini-
cal hold. However these were less common. The challenge is to
identify the studies/compounds prospectively for which inclusion
of recovery animals would be useful, rather than including them
in studies where demonstration of recovery is unnecessary (i.e.
where there is nothing to recover from or where full recovery is
expected). This may involve including recovery animals in later
studies once it is known whether there is something to recover
from.4.4. Science-based consideration
Despite the common approach to include recovery animals in
all studies, there is a precedent for science-based consideration.
Some companies do not include recovery animals unless there
are case-speciﬁc reasons (i.e. it is ‘default’ practice not to include
recovery animals). There are examples of compounds where
recovery animals were not included on any pivotal study prior to
FIH (25 compounds from 8 companies; including 6 biologicals
and 18 small molecules). Reasons given for exclusion included
‘company practice’, ‘no indication of need’ and ‘lack of signal in
prior in vivo studies’. The impact of exclusion of recovery animals
for these compounds was reported as ‘none’. Contrary to inclusion
of recovery animals, this term (i.e. impact ‘none’) is less ambiguous
when considering the impact of exclusion of recovery animals. At a
regulatory level, we know the compounds that subsequently
entered Phase I were able to do so in the absence of recovery data:
speciﬁcally 22/25 compounds that did not include recovery in any
study successfully entered Phase I. The 3 compounds that did not
enter Phase I trials were discontinued earlier in development for
reasons unrelated to recovery.
Similarly, in 2008, Baldrick reported that in an evaluation of 34
FIH preclinical programmes with small molecules, 25 (74%) of
these successfully entered clinical development without the inclu-
sion of recovery groups, in either the rodent or non-rodent toxicol-
ogy studies. This differs from our dataset, where only 18/78 (24%)
small molecules did not include recovery animals, but were still
able to enter FIH. Baldrick examined Investigator’s Brochures used
to support FIH from a 10 year period (1997–2006), whereas our
dataset was collected from studies completed since January 2010.
The difference may reﬂect changes in the regulatory environment
(e.g. the revision and addendum of ICH M3 and ICH S6 guidelines
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the pharmaceutical industry.
There was a small proportion of compounds that included
recovery animals in some, but not all, studies. For these com-
pounds, an impact of exclusion was rarely reported. There were
only three cases where an impact was described; two cases where
a repeat study was required and another where the impact was
marked as ‘unknown’ as the compound had not yet gone into clin-
ical trials at the time of the questionnaire. Therefore, of all the
studies that excluded recovery animals (69/259 studies), which
comprises studies from compounds that included recovery animals
in ‘some’ or ‘no’ studies, an impact was only reported in 3/69 stud-
ies (4.3%). The impact was described as ‘unknown’ for one of these
studies, whereas repeat studies with inclusion of recovery animals
were required for the remaining two. This demonstrates that
where inclusion of recovery animals was not thought to be neces-
sary, based on existing information from previous studies with the
compound or other sources, there is limited risk associated with
exclusion: speciﬁcally, repeated studies to assess recovery are
rarely required.
4.5. Scientiﬁc justiﬁcations – when to include recovery animals
One of the reasons for starting this inquiry was anecdotal evi-
dence suggesting that the industry may be moving towards the
inclusion of recovery animals inmore studies, pairedwith the desire
of the working group to maintain a scientiﬁcally driven case-
by-case approach. The working group recommends that recovery
animals should only be included in studies to support FIH if there
is a positive indication of need. This decision can be made through
robust scientiﬁc assessment, where recovery animals are only
included in situations where the weight-of-evidence points to a
need to assess reversibility from a toxic effect using animals.Fig. 4. A consideration tree to help inform decisions on when and hoThe working group has used the results of this analysis and
their own experience to develop a list of circumstances where
inclusion of recovery animals might be justiﬁed (Table 12). For
clarity, a list of scenarios when inclusion of recovery animals
may not be warranted has also been developed. This is the consen-
sus opinion of the working group, which includes representation
from 30 organisations, including pharmaceutical and biotechnol-
ogy companies, contract research organisations, academia and reg-
ulatory bodies. The table is intended for use as a guide to identify
appropriate situations for the inclusion of recovery animals, to
minimise animal use, costs and resources, whilst avoiding risk to
drug development and human safety.
Information from earlier studies should be used to make
case-speciﬁc decisions on whether data from recovery animals
are necessary. This could include previous non-clinical data on
the compound itself or a related one, or clinical experience with
the class of drug. If information from earlier internal studies is
not available, evidence from the literature or the known mecha-
nism of action may indicate whether assessment of recovery
animals is necessary at a given stage of drug development. If the
existing information is adequate to assess reversibility of any
potential ﬁnding then recovery animals do not need to be included.
In situations where there is a lack of knowledge surrounding
the potential reversibility of the toxicity seen in previous studies,
and/or the type of lesion that may occur, then inclusion of recovery
animals may be warranted. However, in most cases, it may be
appropriate to delay assessment of recovery until more informa-
tion is available (i.e. in later studies when it is known whether
there is any toxicity from which to recover or if a scientiﬁc assess-
ment would be adequate). If recovery assessment were postponed
until after the initial safety studies to support FIH, the information
generated from these studies can be used to make an informed
decision on whether inclusion of recovery animals in later studiesw to include recovery animals in the development programme.
Table 13
All compounds: summary of the current approach to inclusion of recovery animals in studies conducted in mouse, rat, dog or NHP, using examples of the minimum and maximum
approaches from the dataset (the number of dose groups recovery animals were included on, the number of recovery animals per group and the total number of recovery animals
included per study).
Most common approach
Species No. dose groups with recovery animals No. recovery animals per group No. recovery animals per study
Mouse No common design No common design No common design
Rat Con + 1 5M + 5F 20
Dog Con + 1 2M + 2F 8
NHP Con + 1 2M + 2F 8
Range in practice
Species No. dose groups with recovery animals No. recovery animals per group No. recovery animals per study
Min Max Min Max Min Max
Mouse Con + 1 Con + 4 5M + 5F 12M + 12F 20 96
Rat Con + 1 Con + 4 3M + 3F 10M + 10F 12 100
Dog Con + 1 Con + 3 2M + 2F 4M + 4F 8 18
NHP Con + 1 Con + 5 2M + 2F 5M + 5F 8 50
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studies and reduce unnecessary animal use.
In view of the variability of the designs of preliminary in vivo
toxicology studies, another consideration may be to include addi-
tional pathology (both histopathology and clinical pathology) into
the initial non-clinical studies, in order to give some advanced
warning on potential ﬁndings which could help in the design of
later studies, including the decision on the need to assess revers-
ibility. Although this may increase the ﬁnancial cost of a prelimin-
ary study, it could potentially reduce the cost for the pivotal
general toxicity study intended to support the FIH trial through
reduced animal use. This may be particularly appropriate for small
molecules. However, for biologicals where recovery from exagger-
ated pharmacology may need to be demonstrated the decision on
when to include recovery animals during the development pro-
gramme may be different.
4.6. Recommendations for study design
Recovery animals are included primarily to address one speciﬁc
study objective, and that is to provide information on the revers-
ibility of any treatment-related ﬁnding (though in rare cases they
may identify delayed toxicity). If inclusion of recovery animals is
scientiﬁcally justiﬁed, this can be performed using a well-consid-
ered study design. Accordingly, recovery animals do not necessar-
ily need to be included in every study or on every dose group. The
use of a study design that provides both adequate scientiﬁc infor-
mation and an opportunity to reduce animal use is encouraged.
The expert industry working group have used their combined
experience and expertise to give a series of considerations for
study designs (Fig. 4). This is designed to be used in conjunction
with Table 12, which provides a list of circumstances where
inclusion of recovery animals may or may not be justiﬁed. Consid-
erations include in which species to assess reversibility (rodent vs.
non-rodent), the number of dose groups, and the number of
animals per group, taking into account the range of different
approaches utilised in this dataset (Table 13). There were large
variations in the total number of animals used per study, depend-
ing on the number of dose groups that included recovery animals
and the number of animals per group. For each species, Table 13
shows the most common approach used and the minimum and
maximum approaches used.
In our dataset, when recovery animals were used they were
generally included in one rodent and one non-rodent study. It
should be a rare circumstance where recovery animals are needed
in both rodent and non-rodent species. For example this may be
appropriate if the toxicity is different in the different species and
the reversibility for both species is unknown.Recovery animals only need to be included at one appropriate
dose level, rather than all dose levels. The dose level of choice is
often the high dose group but there may be situations where the
high dose is not the most appropriate. For biologics, for example,
the high dose is not always clinically relevant, and inclusion in a
lower dose group may be more appropriate.
A control recovery dose group may not always be necessary,
particularly for non-rodents. In the absence of a control recovery
group, the individual results for in-life evaluations at the end of
the treatment period for each dose group can be compared with
those at the end of the recovery period in the same animals to
assess whether there has been a return to normal, so that each ani-
mal acts as its own control. For histopathology, reference can also
be made to a historical control dataset (Konigsson, 2010). In the
case of short recovery periods and with sexually mature animals,
there is minimal risk of age-related phenotypic drifts, particularly
in non-rodent studies. However, for studies with longer recovery
periods and/or where juvenile or adolescent animals are used
exclusion of the control recovery group may not always be appro-
priate. This especially applies to rodent studies, where the contri-
bution of age-related phenotypic drifts may be more signiﬁcant.
Generally, unless there are speciﬁc reasons for large group sizes
(e.g. satellite groups for TK in rodents) minimal numbers of recov-
ery animals should be used in each recovery group. The size of the
recovery group used in any particular study may depend on the
nature and prevalence of the expected toxicity. It is desirable to
use the minimum number of animals required to achieve the
answer to the scientiﬁc question. From the data obtained in the
survey, the most common sizes for recovery animal groups were
2M + 2F for non-rodents and 5M + 5F for rodents.
Whether both male and female recovery groups are required
should be driven by whether the lesion is seen in both sexes. Even
so, if reversible in one gender, one would expect that this would
reverse in both, and it may therefore be more appropriate to include
adequate numbers in a single sex, rather than assess in both.
Overall, the data analysis shows that there is a precedent for
science-based considerations regarding inclusion of recovery
animals in repeat-dose toxicology studies. A common rationale
for including or not including recovery animals in pivotal GLP stud-
ies was listed as being based on a signal (or lack thereof) from pre-
vious in vivo studies. This suggests that decisions on inclusion of
recovery animals in pivotal studies may be effectively based on
existing exploratory data or literature information in many cases.
Therefore, consideration of such information should be encouraged
in all cases as a means to reduce the number of animals used in
recovery assessments. There were examples from our dataset that
indicated minimal risk or impact when recovery animals were
excluded from FIH studies in speciﬁc, case-by-case situations.
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were able to successfully enter Phase I, in the absence of recovery
data. The expert group has used the evidence-base and their com-
bined expertise and experience to provide guidance on appropriate
situations for the inclusion of recovery animals, to minimise animal
use, costs and resources, whilst avoiding risk to drug development
and human safety. By reviewing the impacts of inclusion, and pro-
viding examples of where exclusion has been appropriate, we can
address the common misconception that inclusion of recovery ani-
mals is a universal regulatory requirement.
5. Conclusions
The dataset used for this assessment demonstrated a wide
range of approaches to the inclusion of recovery animals to support
FIH clinical studies, despite the common goal to meet global regu-
latory expectations. There are several examples where the absence
of recovery animals had no impact on the regulatory processes. The
approaches for small molecules and biologics were often different
because of the nature of the materials.
The expert working group therefore has the following
recommendations:
(1) Recovery phase animals are not included into any FIH non-
clinical study design as default and should only be included
for scientiﬁc reasons (Table 12).
(2) Inclusion of recovery phase animals should be considered
across the whole development programme as well as indi-
vidual studies to minimise animal use.
(3) The designs of the preliminary non-GLP studies should be
carefully considered in order to obtain information so that
an informed decision on the necessity to include recovery
animals in the GLP-studies can be made.
(4) Consideration should be given to including recovery animals
in later (rather than earlier) studies, where possible, once
information on the toxicity proﬁle is known.
(5) Consideration should be given to the most appropriate spe-
cies (rodent vs. non-rodent) and sex in which to assess
reversibility.
(6) The recovery group size should be kept to the minimum
required to answer the scientiﬁc question, dependent on
the nature and prevalence of the expected toxicity.
(7) The number of groups to which recovery phase animals are
added should be kept to a minimum (e.g. control and one
clinically relevant dose group only).
(8) For non-rodents, consideration should be given to not
including recovery animals in the control group.
These recommendations, whilst not inﬂuencing the regulatory
acceptability of any study, will result in a signiﬁcant global reduc-
tion in the numbers of animals used to support FIH toxicity studies.Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.yrtph.2014.07.
018.
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